Figma Shares Indicated To Open $105/$110
Deborah M. Messemer, a director at Allogene Therapeutics, Inc. (NASDAQ:ALLO), recently sold 13,313 shares of the company’s common stock. The company, which maintains a strong balance sheet with more cash than debt, has seen its stock surge 84% in the past week. The shares were sold on February 18, 2025, at a weighted average price of $2.43 per share, totaling approximately $32,350. This transaction was carried out under a Rule 10b5-1 trading plan that Messemer adopted on August 30, 2024. According to InvestingPro analysis, the stock appears fairly valued, with investors anticipating the company’s upcoming earnings report on February 26. Following this sale, Messemer holds 144,316 shares of Allogene Therapeutics directly. The shares were sold in multiple transactions with prices ranging from $2.42 to $2.44. InvestingPro subscribers can access 13 additional key insights about ALLO’s financial health and market position through the comprehensive Pro Research Report.
In other recent news, Allogene Therapeutics, Inc. has reported promising results from its Phase 1 ALPHA and ALPHA2 clinical trials for its CAR T therapy, cemacabtagene ansegedleucel (cema-cel), in patients with relapsed/refractory large B-cell lymphoma (LBCL). The trials demonstrated an overall response rate of 58% and a complete response rate of 42%, with improved rates of 67% and 58% in the pivotal study regimen. Notably, the median duration of response for patients achieving complete response was 23.1 months, and the median overall survival has not yet been reached. Additionally, the safety profile was manageable, with no reports of severe side effects such as graft-versus-host disease or high-grade cytokine release syndrome. Cema-cel has also shown potential benefits for patients with low disease burden, achieving a 100% complete response rate in this subgroup. Furthermore, Allogene has announced the upcoming departure of Timothy Moore, an executive officer, effective February 28, 2025. The company plans to enter into a consulting agreement with Moore, with terms currently under negotiation. These developments continue to shape Allogene’s strategic direction in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.